Olverembatinib after stem cell transplant for Ph+ ALL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted therapy called Olverembatinib given after a donor stem cell transplant (allo-HSCT) for a type of leukemia called Ph+ ALL. The drug is used either to prevent relapse or to treat early signs of the disease, and it may help keep you in remission longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of leukemia called Ph+ ALL (Philadelphia chromosome positive or BCR/ABL gene positive).
- You have received a donor stem cell transplant and are at least 30 days past the transplant.
- You are 18 years or older.
- Your kidneys and liver are working well enough (specific lab results required).
- You are not pregnant or breastfeeding.
- You have no uncontrolled infections or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Olverembatinib and Inotuzumab Ozogamicin, given as consolidation therapy before a stem cell transplant for people with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who did not achieve a deep response after initial chemotherapy. The goal is to see if this approach can improve outcomes.
This trial tests a new drug called asciminib given after a stem cell transplant to prevent the return of a type of leukemia. If you have Philadelphia chromosome-positive B-ALL or blast-phase CML, this may help keep you in remission.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.